2023
Topical Management of Plaque Psoriasis-A Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation.
Bruno M, Strober B, Del Rosso J. Topical Management of Plaque Psoriasis-A Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation. The Journal Of Clinical And Aesthetic Dermatology 2023, 16: s3-s12. PMID: 38496799, PMCID: PMC10939505.Peer-Reviewed Original ResearchTopical treatmentTopical treatment of plaque psoriasisTreatment of plaque psoriasisAryl hydrocarbon receptor modulatorsTopical corticosteroid therapyUnited States Food and Drug AdministrationStates Food and Drug AdministrationTreatment of psoriasisFood and Drug AdministrationEffective mechanism of actionCorticosteroid therapyPlaque psoriasisTopical therapyTreatment armamentariumModulator therapyMechanism of actionNonsteroidal agentsReceptor modulatorsAryl hydrocarbon receptorFDA approvalDrug AdministrationModulating agentsPsoriasisTherapyDermatology community
2022
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Strober B, Stein Gold L, Bissonnette R, Armstrong A, Blauvelt A, Kircik L, Brown P, Tallman A, Lebwohl M. Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent. SKIN The Journal Of Cutaneous Medicine 2022, 6: s5. DOI: 10.25251/skin.6.supp.5.Peer-Reviewed Original Research
2021
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Strober B, Stein Gold L, Bissonnette R, Armstrong A, Blauvelt A, Brown P, Kircik L, Tallman A, Lebwohl M. Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent. SKIN The Journal Of Cutaneous Medicine 2021, 5: s35. DOI: 10.25251/skin.5.supp.35.Peer-Reviewed Original Research